ABSTRACT: An in vitro study of protein binding has been carried out to observe the influence of atenolol and zinc chloride on the protein binding of amlodipine by equilibrium dialysis method at 37±1 0 C and at physiological pH (7.4). It has been found that zinc chloride lowered the affinity and percentage of protein binding of amlodipine to bovine serum albumin but atenolol has no such effect. The Scatchard plots were prepared to reveal the number of binding sites and the affinity for protein binding. It was seen that the highest percentage binding of amlodipine was 91% and the lowest was 74%. In the presence of atenolol, the highest and the lowest value of percentage of protein binding was 90% and 72%, respectively. In the presence of zinc chloride these values were 84% and 65% respectively. It is, thus, inferred that atenolol or its complex with amlodipine has no significant effect on percentage of protein binding of amlodipine. While zinc chloride or its complex with amlodipine can cause a decrease in percentage of protein binding of amlodipine. Complexation of amlodipine with zinc chloride might, therefore, displace the drug from the plasma and the displaced drugs may be redistributed, thus , increasing the free drug in plasma and tissue systems. This may change the pharmacokinetic properties of the drug and may affect the pharmacological and toxic effects. It is thus inferred that care and monitoring must be taken during combination therapy of amlodipine and zinc chloride.
INTRODUCTION
Amlodipine is an important calcium channel blocker which has gained wide acceptance in the treatment of various types of cardiovascular diseases such as angina pectoris, hypertension and cardiac arrhythmias. 1, 2 Atenolol is a beta blocker and used in the indications same as amlodipine. Zinc chloride is an important metal ion indicated for growth retardation, diarrhea, respirtory tract infection (RTI), congenital malformations, mental disturbances, dermatitis, immunological disturbances etc. 3, 4 The chemical structures of all these agents are given in Plasma protein binding is one of the important and useful pharmacokinetic parameters of a drug. There are multiple binding sites on a protein molecule. The pharmacokinetic and pharmacodynamic behavior of a drug are governed by the strength of a complex formed with the protein. Drugs generally form reversible complexes with the plasma proteins that act as a reservior releasing the free drug to the circulation. Free form (of the drug) shows pharmacologic response, is metabolized and excreted. Bound (to the plasma protein) drug is gradually released to maintain the equilibrium and thus the pharmacologic response is maintained. The type and nature of protein binding depend on the physicochemical properties of the drug molecules, their concentration, pH of the medium and also on the concentration and number of available binding sites of the plasma proteins. Protein binding of a drug is a limiting factor for drug effect. Simultaneous administration of two or more drugs into the systemic circulation can modify the affinity of the drug to bind with plasma protein and thus percentage of protein binding. Due to this modification, the combined therapy can change the volume of distribution, renal and hepatic clearance, and hence drug effect. 5, 6 This study was aimed to evaluate the influence of atenolol and zinc chloride on the percentage of protein binding at physiological conditions (pH 7.4 and temperature 37 ± 1ºC) and thus to infer about the combination therapy. To the best of our knowledge, there was no report on the study of effect of protein binding between amlodipine and atenolol and zinc chloride. The present study, therefore, was aimed to explore the effect of protein binding of atenolol and zinc chloride on amlodipine.
MATERIALS AND METHODS
Drugs and Chemicals. Amlodipine hydrochloride and atenolol were kind gifts from Chemico Pharmaceutical Ltd., Rajshahi, Bangladesh. Bovine serum albumin (Fraction V, 96-98%, Sigma) and semipermeable membrane (Medicell, England) and all other reagents were purchased from BDH (England). Phosphate buffers were prepared following standard methods. 7, 8 Apparatus. A digital pH meter (Jenway, London) was used to adjust the pH of the buffer solutions. A recording UV/VIS spectrophotometer (UV-160, Shimadzu, Japan) was used for the measurement of absorbance of the unbound drugs present in the buffer compartment. A Dunbuff metabolic shaking incubator (GCA corporation, USA) was used to shake the plasma-drug mixtures for the attainment of equilibrium.
Equilibrium dialysis. In this experiment, the membranes were activated by digestion with 1.0M sodium bicarbonate at 70ºC for four hours and washing thoroughly with deionized water and immersing in 1/15M (or, 0.067M) phosphate buffer of pH 7.4. Activated membrane bags (12 cm long, 3.0 ml capacity) were filled with solutions of serum bovine albumin with different concentration of the drugs and their mixtures. The membrane bags were immersed in a fixed amount (50 ml) of phosphate buffer and the system was shaken gently for six hours in a metabolic shaking incubator at 37 ± 1ºC. After completion of dialysis the absorbance of the buffer (outside the membrane bags) was measured at 240 nm and the concentrations of the bound and unbound drugs were found using a standard curve.
Determination of the Lamda max (λ max ) for amlodipine to be used in this work. A stock solution of amlodipine was prepared in small volume of methanol and then working solutions were prepared by diluting with water in all cases. Thus, the aqueous solutions of different concentrations of amlodipine (as Active Pharmaceutical Iingredient, not as marketted product) (20-100µM) were prepared and their absorbance was measured to findout the λ max of amlodipine (Figure 2a-c and d) and it was
observed that for amlodipine maximum absorption was occurred at 240 nm in aqueous sulution and the subsequent work was performed using this value as the λ max for amlodipine, although BP suggests 360nm as λ max for marketted product of amlodipine in acidic solution. 9 Then the solution of different concentration of amlodipine were prepared in this buffer and their absorbance was measured at 240 nm which is the λ max of amlodipine. A standard curve was made by plotting absorbance against the concentration of amlodipine ( Figure 3 ).
Preparation of standard curve.
A standard curve was used for the spectrophotometric determination of concentration of drugs in the buffer chamber. A treated buffer was used for this purpose. This buffer was obtained by allowing the equilibrium dialysis of the permeable fragments of free plasma from the inside of the membrane bags to the buffer solution (0.067M phosphate, pH 7.4.).
Calculation of percentage of protein binding. The percentage of protein binding (F) is given by
Where, A =Molar concentration of free drug in buffer compartment B= Molar concentration of total drug in protein compartment Statistics. Data were presented as mean ± S.E.M. Differences in mean values between experimental data were analyzed, where necessary, by unpaired 't' test. A probability value of 0.05 (p<0.05) was defined to be significant. Data were analyzed by the software graphpadPrism.
RESULTS AND DISCUSSION
The invitro determination of percentage of protein binding of amlodipine and its 1 : 1 mixtures of atenolol and zinc chloride has been conducted at room temperature and pH 7.4. The highest percentage of amlodipine binding with bovine serum albumin was found to be 90%. The percentage of protein binding of amlodipine has been found to increase with increase of the concentration of amlodipine which attained a steady plateau state when the free amlodipine concentration was around 5 × 10 -5 M. This might be the saturation zone for the protein binding of amlodipine (Figure 4a ). It was observed that, atenolol did not affect the protein binding profile of amlodipine (Mean ± SEM, ns, not significant because p= 0.7868) (Figure 4b ). This might be due to formation of highly reversible complexes between amlodipine and atenolol. On the otherhand, zinc chloride was found to significantly decrease (mean ± SEM, *significant because p= 0.0454) the percentage of protein binding of amlodipine at the concentration range used but the attainment of steady plateau condition remained unchanged (Figure 4c ). In otherwords, the complex formation of zinc chloride with amlodipine can increase unbound fraction in plasma at high concentrations. This might alter the therapeutic response, toxic effects and pharmacologic properties of amlodipine. These findings are similar to our previous findings. 12, 13 It was also observed that all forms of the drugs (amlodipine and its 1 : 1 mixtures with atenolol and zinc chloride) attained a steady plateau condition at higher concentrations. This indicated the saturation of the sites of protein by the drugs or its complexes as was observed by other investigators.
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The concentration of drugs or the drug mixture were kept within 1x10 -5 M to 8x10 -5 M, while that of bovine serum albumin was kept at 5x10 -5 It can therefore be inferred that complexation of amlodipine with the drugs being studied can displace the drug from the plasma. Since the drug displaced from the plasma protein will redistribute into its full potential volume of distribution, the concentration of free drug in plasma and tissues after redistribution might be increased greatly and this might change the pharmacokinetic propeties of the drug and thereby may affect its pharmacologic and toxic effects.
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Care and monitoring should, therefore, be exercised during combination therapy with such drugs, specially zinc chloride.
It was found that there are al least two binding sites for amlodipine and its complexes with atenolol and zinc chloride ( Figure 5 to Figure 7 , and Table 1 The number of binding sites (n 1 ) in class I was found to be 1.26, 1.14 and 1.28 for amlodipine, amlodipine-atenolol and amlodipine-zinc chloride systems, respectively. The values of affinity constants (K 1 ) with these class of sites have been found to be 107.5, 95.9 and 68.8 , respectively. The number of binding sites (n 2 ) in class II was found to be 0.16, 0.15 and 0.16 for amlodipine, amlodipine-atenolol and amlodipine-zinc chloride systems, respectively. The affinity constants (K 2 ) with them were 180, 176 and 130 for amlodipine, amlodipine-atenolol and amlodipine-zinc chloride systems, respectively.
It is obvious, from these results, that the values of affinity constants for amlodipine is higher than that of its 1 : 1 complexes with atenolol and zinc chloride, i.e., the presence of atenolol and zinc chloride with amlodipine at physiological temperature and pH conditions cause a decrease in values of affinity constats or binding forces specially at lower concentrations as change in higher concentrations of plateau state is negligible. Due to this decrease in affinity of the drug to plasma protein binding, the volume of distribution of amlodipine may increase because affinity of a drug for protein binding is a limiting factor for the distibution of the drug. 17 The values of affinity constants in class II binding sites revealed the same results, i.e., increase in volume of distribution of amlodipine. 16 It is known that amlodipine undergoes heavy first pass metabolism and metabolized by liver. 18 It is excreted through urine and its half life is 3.7±1.2 hour. It was observed that the affinity for protein is lower for 1:1 complexes of amlodipine with atenolol and zinc chloride than that of amlodipine alone. As a result the intake of amlodipine as atenolol or zinc chloride complex or the concurrent therapy might increase both the hepatic and renal clearance of the drug as well as it may decrease the half life of the drug.
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CONCLUSION
Polypharmacy, that is, prescribing many drugs at a time is a common practice in case of patients undergoing a major operation, hospitalized patients, and also in jeriatric patients. Sometimes coadministration of more than two different classes of drugs may ensue effects that are neither safe nor effective but sometimes may be beneficial. It was observed that atenolol and zinc chloride lowerd the affinity of protein binding of amlodipine, and hence an increase in volume of distribution of amlodipine might be occured. Therefore, it can be inferred that care and monitoring should be practised during administration of amlodipine-atenolol and amlodipine-zinc chloride complexes or concurrent administration of amlodipine with atenolol and zinc chloride.
